NCT03549000 - A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

October 17, 2022

Study Completion Date

October 17, 2022

Conditions

Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer (TNBC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer Microsatellite Stable (MSS)Ovarian CancerRenal Cell Carcinoma (RCC)Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

OTHER

NZV930

NZV930, Specified dose on specified days, intravenous (IV)

OTHER

PDR001

PDR001, Specified dose on specified days, intravenous (IV)

DRUG

NIR178

NIR178 Specified dose on specified days, Orally

Trial Locations (10)

3000

Novartis Investigative Site, Melbourne

28009

Novartis Investigative Site, Madrid

33612

H Lee Moffitt Cancer Center and Research Institute Inc, Tampa

46010

Novartis Investigative Site, Valencia

77030

University of Texas MD Anderson Cancer Center MD Anderson PSC, Houston

169610

Novartis Investigative Site, Singapore

M5G 1Z6

Novartis Investigative Site, Toronto

H2W 1T8

Novartis Investigative Site, Montreal

104 0045

Novartis Investigative Site, Chuo Ku

SM2 5PT

Novartis Investigative Site, Sutton